Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Alhemo's Real-World safety in hemophilia patients

NCT ID NCT06831734

ENROLLING_BY_INVITATION Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 30 people with hemophilia A or B (without inhibitors) in Japan who are already using Alhemo (concizumab) as part of their routine care. Researchers will monitor side effects and how well the drug works over about 2 years per person. The goal is to see if Alhemo remains safe and effective in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Concizumab (Alhemo)
What this could lead to
If successful, this study could confirm that Alhemo is safe and effective for long-term use in people with hemophilia A or B without inhibitors, supporting its routine use.
What could go wrong
This is an observational study with only 30 participants, so results may not apply to everyone. It does not test a new treatment, just monitors existing use, and unexpected side effects could still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A, HAEMOPHILIA B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia hemophilia A hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMOPHILIA A, HAEMOPHILIA B

Contacts and locations

Locations

  • Arin Clinic Shonika_Pediatrics

    Okinawa, 901-2132, Japan

  • Chiba university hospital_Pediatrics

    Chiba, 260-8677, Japan

  • Fukaya Red Cross Hospital_Haematology

    Saitama, 366-0052, Japan

  • Hamamatsu Medical Center_Pediatrics

    Shizuoka, 432-8580, Japan

  • Hoshi General Hospital_Pediatrics

    Fukushima, 963-8501, Japan

  • Hyogo Prefectural Amagasaki General Medical Center_Haematology

    Hyōgo, 660-8550, Japan

  • Ishiyama Clinic

    Yamagata, 992-0035, Japan

  • Iwata City Hospital_Haematology

    Shizuoka, 438-8550, Japan

  • Kansai Medical University Hospital_Pediatrics

    Osaka, 573-1191, Japan

  • Matsue red cross hospital_Pediatrics

    Shimane, 690-8506, Japan

  • Miyagi Children's Hospital_Hematology-Oncology

    Miyagi, 989-3126, Japan

  • Nagano Children's Hospital_Hematology-Oncology

    Nagano, 399-8288, Japan

  • Nagano red cross hospital_Pediatrics

    Nahano, 380-8582, Japan

  • Nanbu Medical Center & Children's Medical Center_Pediatric Hematology

    Okinawa, 901-1193, Japan

  • National Center for Child Health and Development_Hematology

    Tokyo, 157-8535, Japan

  • National Hospital Organization Awara Hospital_Hematology and Oncology

    Fukui, 910-4272, Japan

  • Ogikubo Hospital_Blood Coagulation

    Tokyo, 167-0035, Japan

  • Saitama Children's Med Centre_Hematology-Oncology

    Saitama, 330-8777, Japan

  • Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy

    Kawagoe, Japan

  • Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy

    Saitama, 350-8550, Japan

  • St. Marianna Univ., Yokohama City Seibu HP, Pediatrics Dept,

    Yokohama-shi, Kanagawa, 241-0811, Japan

  • St. Marianna University School of Medicine Hospital_Pediatrics

    Kanagawa, 216-8511, Japan

  • University of the Ryukyus Hospital_Endocrinology and Metabolism, Hematology and Rheumatology

    Okinawa, 901-2725, Japan